Phosphodiesterase inhibitors in airways disease
- 2 February 2006
- journal article
- review article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 533 (1-3), 110-117
- https://doi.org/10.1016/j.ejphar.2005.12.059
Abstract
No abstract availableKeywords
This publication has 61 references indexed in Scilit:
- PDE4 inhibitors as new anti-inflammatory drugs: Effects on cell trafficking and cell adhesion molecules expressionPharmacology & Therapeutics, 2005
- Phosphodiesterase 4 inhibition decreases MUC5AC expression induced by epidermal growth factor in human airway epithelial cellsThorax, 2005
- Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokersAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2004
- Modulation of matrix metalloproteinase production from human lung fibroblasts by type 4 phosphodiesterase inhibitorsLife Sciences, 2004
- Clinical efficacy of sildenafil in primary pulmonary hypertensionJournal of the American College of Cardiology, 2004
- In Vivo Efficacy in Airway Disease Models ofN-(3,5-Dichloropyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic Acid Amide (AWD 12-281), a Selective Phosphodiesterase 4 Inhibitor for Inhaled AdministrationJournal of Pharmacology and Experimental Therapeutics, 2003
- Effect of cilomilast (Ariflo) on TNF- , IL-8, and GM-CSF release by airway cells of patients with COPDThorax, 2003
- The New Phosphodiesterase 4 Inhibitor Roflumilast Is Efficacious in Exercise‐Induced Asthma and Leads to Suppression of LPS‐Stimulated TNF‐α Ex VivoThe Journal of Clinical Pharmacology, 2002
- Does Sildenafil Also Improve Breathing?Chest, 2001
- PDE isoenzymes as targets for anti-asthma drugsEuropean Respiratory Journal, 1995